2.Translational medicine and its application in research & development of integrative medicine.
Chinese Journal of Integrated Traditional and Western Medicine 2010;30(10):1017-1020
The background, concept and status quo of translational medicine at home and abroad were introduced systematically in this review, and the application mode of translational medicine in the research and development of Chinese medicine (CM) was analyzed. Targeting the characteristics of CM and the changes in the spectrum of diseases in China, some suggestions were made to strengthen the translational research in CM and integrative medicine.
China
;
Humans
;
Integrative Medicine
;
methods
;
Translational Medical Research
3.Application and development of patient-derived tumor xenograft model in translational medicine of tumor.
Zhenqiang WANG ; Zhenggang ZHU
Chinese Journal of Gastrointestinal Surgery 2017;20(5):596-600
Development of novel drugs is an integral part of the translational medicine in the field of cancer research, and the construction and application of preclinical animal models play vital roles in drugs development. Patient-derived tumor xenograft models (PDX) have been shown to be more accurate in prediction of clinical outcomes of novel drugs and are being used for preclinical drug evaluation based on the fact that PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor. To set up PDX model, primary or metastatic tumor are achieved to translate into immune-deficiency mice. The tumor in immune-deficiency mouse is acquired to translate to other immune-deficiency mouse to generate stable PDX model, which usually is affected by the strain of mouse, translation method and translation location in mouse. PDX models recapitulate the same histology and gene expression as the original patients' carcinoma. PDX models can accurately predict the effectiveness of novel drugs, screen more predictive biomarker for drug resistance and optimize the use of classic drugs in clinic. However, sole source of surgical resection of tumor, long time of construction, high failure rate and hardly used in evaluating immune drugs would be the barriers to be overcome to improve PDX models. The methodological issues, salient features, practical applications, and future directions of PDX models will be illustrated.
Animals
;
Heterografts
;
Humans
;
Mice
;
Neoplasm Transplantation
;
methods
;
Neoplasms
;
physiopathology
;
surgery
;
Translational Medical Research
;
methods
5.Challenges and pitfalls in the introduction of pharmacogenetics for cancer.
Annals of the Academy of Medicine, Singapore 2011;40(8):369-374
There have been several success stories in the field of pharmacogenetics in recent years, including the analysis of HER2 amplification for trastuzumab selection in breast cancer and VKORC1 genotyping for warfarin dosing in thrombosis. Encouraging results from these studies suggest that genetic factors may indeed be important determinants of drug response and toxicity for at least some drugs. However, to apply pharmacogenetics appropriately, a thorough understanding of the scope and limitations of this field is required. The challenges include an appreciation of biological variability, logistical issues pertaining to the proper management of information, the need for robust methods and adequate sample quality with well-designed workflows. At the same time, the economics of pharmacogenetic testing from the perspective of clinicians, patients, governments, insurance companies and pharmaceutical companies will play an important role in determining its future use. Ethical considerations such as informed consent and patient privacy, as well as the role of regulatory bodies in addressing these issues, must be fully understood. Only once these issues are properly dealt with can the full benefits of pharmacogenetics begin to be realised.
Antineoplastic Agents
;
pharmacology
;
Genetic Privacy
;
ethics
;
Humans
;
Informed Consent
;
Neoplasms
;
drug therapy
;
Pharmacogenetics
;
ethics
;
methods
;
Translational Medical Research
;
methods
6.Asian Society of Gynecologic Oncology International Workshop 2014.
Jeong Yeol PARK ; Hextan Yuen Sheung NGAN ; Won PARK ; Zeyi CAO ; Xiaohua WU ; Woong JU ; Hyun Hoon CHUNG ; Suk Joon CHANG ; Sang Yoon PARK ; Sang Young RYU ; Jae Hoon KIM ; Chi Heum CHO ; Keun Ho LEE ; Jeong Won LEE ; Suresh KUMARASAMY ; Jae Weon KIM ; Sarikapan WILAILAK ; Byoung Gie KIM ; Dae Yeon KIM ; Ikuo KONISHI ; Jae Kwan LEE ; Kung Liahng WANG ; Joo Hyun NAM
Journal of Gynecologic Oncology 2015;26(1):68-74
The Asian Society of Gynecologic Oncology International Workshop 2014 on gynecologic oncology was held in Asan Medical Center, Seoul, Korea on the 23rd to 24th August 2014. A total of 179 participants from 17 countries participated in the workshop, and the up-to-date findings on the management of gynecologic cancers were presented and discussed. This meeting focused on the new trends in the management of cervical cancer, fertility-sparing management of gynecologic cancers, surgical management of gynecologic cancers, and recent advances in translational research on gynecologic cancers.
Female
;
Fertility Preservation/methods
;
Genital Neoplasms, Female/*therapy
;
Humans
;
Ovarian Neoplasms/therapy
;
Translational Medical Research/methods
;
Uterine Cervical Neoplasms/therapy
7.Strategy and core technologies for the secondary development of Chinese patent medicine.
Bo-Li ZHAGN ; Xiao-Hui FAN ; Yang LIU ; Hai-Bin QU ; Jun-Hua ZHANG ; Yi-Yu CHEGN
China Journal of Chinese Materia Medica 2013;38(22):3797-3800
Secondary development of Chinese Patent Medicine (CPM) is an effective and innovation-driven way for the leaping development of Chinese medicine industry with less investment and faster return. Aim to improving the efficacy, safety and batch-to-batch consistency of CPMs, the theory and methodology for the secondary development of CPMs, mode for cultivating superior CPM, approaches to reforming the pharmaceutical technology and the corresponding core technologies were proposed in this paper, which is summarized as 'One objective, Three analyses, Five definitudes and Seven improvements'.
Drugs, Chinese Herbal
;
chemistry
;
economics
;
Patents as Topic
;
Technology, Pharmaceutical
;
economics
;
legislation & jurisprudence
;
methods
;
Translational Medical Research
;
economics
;
legislation & jurisprudence
;
methods
9.Translational approach for pharmacogenomics and personalized medicine.
Acta Pharmaceutica Sinica 2011;46(1):1-5
Pharmacogenetics and pharmacogenomics are promising fields that will enable personalized therapy. However, one of the most important issues to be conquered in the practice of personalized medicine is the translation of scientific discoveries into better therapeutic outcomes. The international pharmacogenetic and pharmacogenomic approaches made in the field of personalized medicine and drug discovery are summarized in this review.
Drug Discovery
;
methods
;
Genome-Wide Association Study
;
High-Throughput Nucleotide Sequencing
;
Humans
;
Pharmacogenetics
;
methods
;
Precision Medicine
;
methods
;
Translational Medical Research
;
methods
10.Are You "Tilting at Windmills" or Undertaking a Valid Clinical Trial?.
John D STEEVES ; Jose ZARIFFA ; John L K KRAMER
Yonsei Medical Journal 2011;52(5):701-716
In this review, several aspects surrounding the choice of a therapeutic intervention and the conduct of clinical trials are discussed. Some of the background for why human studies have evolved to their current state is also included. Specifically, the following questions have been addressed: 1) What criteria should be used to determine whether a scientific discovery or invention is worthy of translation to human application? 2) What recent scientific advance warrants a deeper understanding of clinical trials by everyone? 3) What are the different types and phases of a clinical trial? 4) What characteristics of a human disorder should be noted, tracked, or stratified for a clinical trial and what inclusion /exclusion criteria are important to enrolling appropriate trial subjects? 5) What are the different study designs that can be used in a clinical trial program? 6) What confounding factors can alter the accurate interpretation of clinical trial outcomes? 7) What are the success rates of clinical trials and what can we learn from previous clinical trials? 8) What are the essential principles for the conduct of valid clinical trials?
Animals
;
Clinical Protocols
;
Clinical Trials as Topic/ethics/*methods
;
Disease Models, Animal
;
Female
;
Humans
;
Male
;
Outcome Assessment (Health Care)
;
Pregnancy
;
Translational Medical Research